



**HAL**  
open science

## COVID-19: an ‘extraterrestrial’ disease?

Elisabeth Paul, Garrett Brown, Mélanie Dechamps, Andreas Kalk,  
Pierre-François Laterre, Bernard Rentier, Valéry Ridde, Martin Zizi

► **To cite this version:**

Elisabeth Paul, Garrett Brown, Mélanie Dechamps, Andreas Kalk, Pierre-François Laterre, et al.. COVID-19: an ‘extraterrestrial’ disease?. *International Journal of Infectious Diseases*, 2021, 110, pp.155-159. 10.1016/j.ijid.2021.07.051 . hal-03485589

**HAL Id: hal-03485589**

**<https://hal.science/hal-03485589>**

Submitted on 15 May 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0  
International License



## Perspective

## COVID-19: an ‘extraterrestrial’ disease?

Elisabeth Paul<sup>1,\*</sup>, Garrett W. Brown<sup>2</sup>, Mélanie Dechamps<sup>3</sup>, Andreas Kalk<sup>4</sup>,  
Pierre-François Laterre<sup>5</sup>, Bernard Rentier<sup>6</sup>, Valéry Ridde<sup>7</sup>, Martin Zizi<sup>8</sup>

<sup>1</sup> School of Public Health, Université Libre de Bruxelles, Brussels, Belgium

<sup>2</sup> Global Health Theme, University of Leeds, Leeds, UK

<sup>3</sup> Cardiovascular ICU, St-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

<sup>4</sup> Kinshasa Country Office, Deutsche Gesellschaft für Internationale Zusammenarbeit, Kinshasa, Democratic Republic of the Congo

<sup>5</sup> Department of Critical Care Medicine, St-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

<sup>6</sup> Rector Emeritus, Prof. Em. Virology & Viral Immunology, Université de Liège, Belgium

<sup>7</sup> CEPED, Institute for Research on Sustainable Development (IRD), IRD-Université de Paris, ERL INSERM SAGESUD, Paris, France

<sup>8</sup> CEO, Aerendir Mobile Inc., Mountain View, CA, USA; formerly Prof. at VUB (Brussels) and KULeuven, ex-CSO Belgian Ministry of Defense



## ARTICLE INFO

## Article history:

Received 17 June 2021

Revised 20 July 2021

Accepted 22 July 2021

## Keywords:

COVID-19

health policy

public health

treatment

health promotion

## ABSTRACT

**Background:** Since the beginning of the pandemic, COVID-19 has been regarded as an exceptional disease. Control measures have exclusively focused on ‘the virus’, while failing to account for other biological and social factors that determine severe forms of the disease.

**Aim:** We argue that although COVID-19 was initially considered a new challenge, justifying extraordinary response measures, this situation has changed – and so should our response.

**Main arguments:** We now know that COVID-19 shares many features of common infectious respiratory diseases, and can now ascertain that SARS-CoV-2 has not suddenly presented new problems. Instead, it has exposed and exacerbated existing problems in health systems and the underlying health of the population. COVID-19 is evidently not an ‘extraterrestrial’ disease. It is a complex zoonotic disease, and it needs to be managed as such, following long-proven principles of medicine and public health.

**Conclusion:** A complex disease cannot be solved through a simple, magic-bullet cure or vaccine. The heterogeneity of population profiles susceptible to developing a severe form of COVID-19 suggests the need to adopt varying, targeted measures that are able to address risk profiles in an appropriate way. The critical role of comorbidities in disease severity calls for short-term, virus-targeted interventions to be complemented with medium-term policies aimed at reducing the burden of comorbidities, as well as mitigating the risk of transition from infection to disease. Strategies required include upstream prevention, early treatment, and consolidation of the health system.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## Background

Although the threat of a pandemic had been present for many years, COVID-19 triggered frantic and uncoordinated reactions worldwide (Independent Panel for Pandemic Preparedness and Response, 2021; Paul et al., 2020b). Since being declared a public health emergency in January 2020, COVID-19 has been regarded as an exceptional disease, almost as if it came from outer space. For the first time in history, billions of people were locked down, denied the right to go to school or to earn their living, and/or to

see their loved ones, while an unprecedented race for treatment and vaccine discovery was launched. The collateral damage from these response measures was largely ignored, even if it may have been greater than the positive effects of the implemented policies (Hrynicky et al., 2021). It ranged from economic recession and loss of education, to increases in domestic violence and mental health problems, and the worsening of chronic conditions from a lack of access to care (Bavli et al., 2020). The effects weighed particularly heavily on young people, and hit the most vulnerable disproportionately, aggravating inequities (Chakrabarti et al., 2021). In many countries, primary healthcare professionals were denied the right to treat their patients. Without effective primary healthcare, hospitals were left with the task of treating severe cases, notwithstanding the absence of a specific recommended drug. This led

\* Corresponding author.

E-mail address: [Elisabeth.Paul@ulb.be](mailto:Elisabeth.Paul@ulb.be) (E. Paul).

to the further exacerbation of existing disparities in health systems and services, especially in low- and middle-income countries (Baral, 2021).

Despite the fact that COVID-19 could be categorised as a ‘syndemic’ (Horton, 2020) – a synergy of epidemics that ‘co-occur in time and place, interact with each other to produce complex sequelae, and share common underlying societal drivers’ (Swinburn et al., 2019) – control measures were exclusively focused on ‘the virus’ and delay tactics, while not taking into account other biological and social factors that contribute to determining severe forms of the disease (Paul et al., 2020a). After several inconclusive results, it was only in July 2020 that one of the two large international randomized controlled trials aimed at testing the efficacy of existing treatments against COVID-19 published a preliminary report showing that dexamethasone (a glucocorticoid) resulted, on average, in lower mortality rates in patients requiring supplemental oxygen or invasive mechanical ventilation (The RECOVERY Collaborative Group, 2020). The lack of evidence on more effective medical treatments, coupled with projections suggesting high disease loads and death tolls, led to the perception that this was a one-off disease. This, unfortunately, led to proven and traditional medical and public-health practices being largely ignored. For instance, the longstanding concept of ‘herd immunity’, which has always represented an objective, or an achievement, is now considered by many as a ‘strategy’ – not to be acquired naturally, but only through vaccination (World Health Organization, 2020). In spite of all its potential risks, limitations, and considerable uncertainties regarding long-term side effects, the duration of protection, and its effectiveness against viral variants, vaccination quickly became the only salvation option promoted by key governments and international institutions.

Although it is understandable that COVID-19 was considered an exceptional disease in early 2020, justifying exceptional response measures – particularly since SARS-CoV-2 can trigger a variety of symptoms, some of them extremely severe (Hu et al., 2020; Wiersinga et al., 2020) – the situation has changed. So should our response (Paul et al., 2020a). In this article, we argue that now that we far better understand the complex functioning of COVID-19, we should adapt our response strategy in a way that addresses its heterogeneity, and embraces proven and traditional medical and public-health practices.

### Analytical approach

Various areas of expertise are relevant to approaching the complexity of the COVID-19 response. This article is based on a collaboration of clinicians, researchers, and experts in public-health policies based in three continents (America, Africa, and Europe) who are concerned by the COVID-19 response strategies in their respective countries – Belgium, Democratic Republic of the Congo, France, Germany, UK, USA – and at the global level. Together, they combine expertise in intensive care practice, biophysics, public health, virology, and health policies and systems. This paper adopts a reflexive analytical approach – where reflexivity can be defined ‘as an intentional intellectual activity in which individuals explore or examine a situation, an issue, or a particular object on the basis of their past experiences to develop new understandings that will ultimately influence their actions’ (Tremblay et al., 2014) – to critically analyze, from a multidisciplinary point of view, the COVID-19 response strategy at the global level.

### COVID-19 exposed existing problems

We now know that COVID-19 shares many features of common infectious respiratory diseases in terms of its transmission process – it is caused by a coronavirus whose transmission is

airborne (Greenhalgh et al., 2021). Its immunopathology is better understood (Cao, 2020) and may entail vascular and immune system dysfunctions, possibly leading to a cytokine storm (Garvin et al., 2020; Varga et al., 2020). Its severity and lethality are largely related to age, social determinants, and comorbidities (Williamson et al., 2020), while its infection–fatality rate, which averages around 0.2–0.3%, is extremely low for young people (Ioannidis, 2020; O’Driscoll et al., 2020). Overall, SARS-CoV-2 has not created new problems out of the blue, but rather has exposed and exacerbated existing problems in the context in which it finds itself. For instance, in the USA, COVID-19 has revealed the poor health status of a large proportion of the population, with two-thirds of COVID-19 hospitalizations attributable to four major cardiometabolic conditions (O’Hearn et al., 2021), the critical role of social determinants of health (Karmakar et al., 2021), as well as ‘deep underlying problems in the healthcare system’ (Blumenthal et al., 2020). In Europe, the pandemic has highlighted the ageing population, a lack of healthcare personnel resources, and the insufficiency of quality primary healthcare (OECD/European Union, 2020). In Brazil, existing socioeconomic inequalities have driven epidemic outcomes more than any other risk factor (Rocha et al., 2021). Above all, COVID-19 has revealed the lack of health-system preparedness for pandemics, with inept global policies, non-existent and outdated national plans, a lack of health-system adaptability, equipment shortages, unreliable availability of medicines, poor communication strategies, fragmented diagnostic capabilities, and poor governance structures (Baral, 2021; Paul et al., 2020b).

### Implications for policy

COVID-19 is not an extraterrestrial disease that appeared from nowhere. It is a complex zoonotic disease and it needs to be managed as such (Wernli et al., 2021), following long-proven principles of medicine and public health. A complex disease cannot be solved through a simple magic-bullet cure or vaccine. This especially true when the infectious agent is an airborne virus with not only one, but many animal reservoirs, being a known zoonosis that can be found in numerous species around human habitats (Shi et al., 2020; Ye et al., 2020; Wardeh et al., 2021; He et al., 2021). As a result, claims for its eradication are naïve. In fact, some scientists are suggesting that ‘full’ herd immunity to end this pandemic is probably impossible because of new variants arising, doubts over whether the vaccines can prevent transmission, signs of waning immunity, and inequities in the global distribution of vaccines (Aschwanden, 2021). This simple fact also renders viral control policies via the increased use of lockdowns unsustainable. According to 50 years of coronavirus research, as well as knowledge accumulated on respiratory viral infections, we should expect new waves of the virus, or of a variant, probably more regularly in fall and winter, particularly in the northern hemisphere (Estola, 1970; Moriyama et al., 2020). This calls for a shift in policy from a ‘zero-risk’ strategy, which is imposed top-down via ‘command-and-control’ lockdowns, to ‘risk-mitigation’ and ‘harm-reduction’ strategies through educating and empowering people, especially the most vulnerable (Arnold, 2021; Loewenson et al., 2021, 2020).

The heterogeneity of population profiles susceptible to developing a severe form of COVID-19 calls for the adoption of varying, targeted measures, which are able to reach risk groups in an appropriate way. The critical role of comorbidities in disease severity calls for complementing short-term virus-targeted interventions – including prophylaxis in high-transmission settings (Seet et al., 2021) – with medium-term procedures aimed at reducing the burden of comorbidities, as well as SARS-CoV-2 infection-to-COVID-19 disease transition risks, at an early stage. The heterogeneity

of COVID-19 symptoms suggests that we should not simply wait for a specific cure that works 'on average' against SARS-CoV-2, at a late stage of the disease. With such heterogeneity, most people's disease development profiles lie far from the average. Moreover, viral infections follow a well-known path from their entry point to ultimate outcomes, requiring the adaptation of treatment to each patient's stage in infection. It is better to start treating before inflammation sets in and to adapt treatments to individual needs, through primary and patient-centred care. For instance, while it has been known since the first wave that COVID-19 causes blood clots, it is only recently that a study has confirmed that prophylactic anticoagulation treatment is probably 'optimal therapy' for COVID-19 patients (Vaughn et al., 2021). Likewise, we should not delay empirical antimicrobial therapy in cases of suspected co-infection prior to the worsening of clinical conditions; the potential benefits of pre-emptive antimicrobial therapy at the time of COVID-19 symptom onset need to be explored appropriately (Contou et al., 2020; Intra et al., 2020; Rawson et al., 2020; Verroken et al., 2020). This point had already been promoted by Dr A Fauci as a conclusion to the flu pandemics of 2008–2009 (Morens et al., 2008). Evidence is now emerging for the potential effectiveness of repurposed drugs, including ivermectin (Hill et al., 2021), amantadine (Cortés-Borra and Aranda-Abreu, 2021), and colofloctol (Belouzard et al., 2021), as well as nutritional supplementation (Alzaabi et al., 2021; Margolin et al., 2021) and new molecules, such as plitidepsin (Varona et al., 2021), at early stages of disease. More research is required at this level. Furthermore, when dealing with patients with known comorbidities, it would be medically sound and therapeutically helpful to carry out typing of the human leukocyte antigen (HLA) for susceptibility, so as to identify those who truly need swifter and deeper care (de Sousa et al., 2020; Langton et al., 2021).

Vaccines are an important part of the response strategy, but only if they follow a precautionary principle, with continuous appraisal of the benefit–risk balance. Doing so is necessary to maintain confidence in vaccines and to avoid adverse effects – as with vaccines against dengue and the influenza H1N1 pandemic (Forcades i Vila, 2015; *The Lancet Infectious Diseases*, 2018) – that could reinforce vaccine hesitancy on the part of people who need it most. However, vaccines alone will not solve the COVID-19 pandemic (SARS-CoV-2 variants: the need for urgent public health action beyond vaccines, 2021). Thus, additional complementary strategies are needed, including prevention, early treatment, and the consolidation of the health system (Paul et al., 2021). Even if it is not recommended by the World Health Organization as a 'strategy', innate and already naturally acquired immunity, including T-cell immunity (Braun et al., 2020), must be taken into account when determining the most appropriate response policies, including the assessment of the hypothetical herd immunity threshold advanced by many governments as a precondition for lifting non-pharmaceutical interventions. Indeed, there is now mounting evidence that SARS-CoV-2 infection induces robust immune responses, regardless of disease severity (Nielsen et al., 2021), and that acquired natural immunity is lasting (Hall et al., 2021; Turner et al., 2021). This suggests that individuals previously infected by SARS-CoV-2 are unlikely to benefit from COVID-19 vaccination, so that vaccines can be safely prioritised to those who have not been infected before (Shrestha et al., 2021).

Non-pharmaceutical interventions continue to be implemented in many countries despite progress in vaccinations – even strict lockdowns (e.g. in Australia) – in spite of lack of evidence on their overall efficiency (McCartney, 2020). For example, nearly a year and a half after the beginning of the pandemic, there is still low evidence for the effectiveness of face mask wearing in community settings (Chou et al., 2021). While some studies show that stay-at-home policies may have reduced virus transmission, others

show that they have not impacted overall mortality (Agrawal et al., 2021). In any case, non-pharmaceutical interventions must be proportional to overall health needs and chosen to take into account local context specificities and existing alternatives, while aiming to maximize expected benefits for general health outcomes and minimize collateral damage. From this perspective, the most efficient measures probably include limiting mass gatherings, promoting outdoor activities, where transmission is very low (Bulfone et al., 2021), implementing sentinel surveillance and smart testing policies (Flandre et al., 2021), and ventilating public indoor places (Bazant and Bush, 2021).

In terms of the policy landscape, public health policies need to be decided and designed in a transparent way, in collaboration with all relevant disciplines and stakeholders, including populations, and social and healthcare workers, and regularly evaluated to ensure continuous adaptation and improvement (Paul et al., 2020a). Moreover, there needs to be a normative shift in how we think about prevention and preparedness, particularly towards a mindset that understands long-term preventative healthcare as an investment, not an expense. Lastly, it is crucial to move beyond our current understanding of health security, which has traditionally favoured surveillance, exceptionalism, 'countermeasures', and an overreliance on vaccine discovery, often at the expense of routine health. As an alternative, the link between health-system strengthening and health security needs to be articulated more forcefully, with better multilevel governance mechanisms for coordinating efforts, integrating community, national, regional, and global levels (World Health Organization, 2021). If not, then the policy lessons from COVID-19 will have been ignored, and we will once again find ourselves confronting the next pandemic as if it were an unexpected and exceptional disease.

## Acknowledgements

The authors thank Wim Van Damme for commenting on a previous version of this paper.

Declaration of interest statement: The authors declare no conflicts of interest.

Ethical approval: This was not required for this perspective paper.

Funding: No specific funding was utilized. All authors are independent from funders.

## References

- Agrawal, V., Cantor, J., Sood, N., Whaley, C.M., 2021. The impact of the COVID-19 pandemic and policy responses on excess mortality (working paper No. 28930), Working Paper Series. National Bureau of Economic Research.
- Alzaabi MM, Hamdy R, Ashmawy NS, Hamoda AM, Alkhatay F, Khademi NN, Al Joud SMA, El-Keblawy AA, Soliman SSM. Flavonoids are promising safe therapy against COVID-19. *Phytochem Rev Proc Phytochem Soc Eur* 2021:1–22. doi:10.1007/s11101-021-09759-z.
- Arnold C. COVID-19: How the lessons of HIV can help end the pandemic. *BMJ* 2021;372:n216. doi:10.1136/bmj.n216.
- Aschwanden C. Five reasons why COVID herd immunity is probably impossible. *Nature* 2021;591. doi:10.1038/d41586-021-00728-2.
- Baral P. Health systems and services during COVID-19: lessons and evidence from previous crises: a rapid scoping review to inform the United Nations research roadmap for the COVID-19 recovery. *Int J Health Serv* 2021 0020731421997088. doi:10.1177/0020731421997088.
- Bavli I, Sutton B, Galea S. Harms of public health interventions against COVID-19 must not be ignored. *BMJ* 2020;371:m4074. doi:10.1136/bmj.m4074.
- Bazant MZ, Bush JWM. A guideline to limit indoor airborne transmission of COVID-19. *Proc Natl Acad Sci* 2021;118. doi:10.1073/pnas.2018995118.
- Belouzard S, Machelart A, Sencio V, Vausselin T, Hoffmann E, Deboosere N, Rouillé Y, Desmaretz L, Séron K, Danneels A, Robil C, Belloy L, Moreau C, Piveteau C, Biela A, Vandeputte A, Heumel S, Deruyter L, Dumont J, Leroux F, Engelmann I, Alidjinou E.K., Hober D, Brodin P, Beghyn T, Trottein F, Déprez B, Dubuisson J, 2021. Large scale screening discovers colofloctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology. *bioRxiv* 2021.06.30.450483. doi:10.1101/2021.06.30.450483

- Blumenthal D, Fowler EJ, Abrams M, Collins SR. COVID-19 – implications for the health care system. *N Engl J Med* 2020;383:1483–8. doi:[10.1056/NEJMs2021088](https://doi.org/10.1056/NEJMs2021088).
- Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, Dingeldey M, Kruse B, Fauchere F, Baysal E, Mangold M, Henze L, Lauster R, Mall MA, Beyer K, Röhm J, Voigt S, Schmitz J, Miltenyi S, Demuth I, Müller MA, Hocke A, Witzentrath M, Suttorp N, Kern F, Reimer U, Wenschuh H, Drosten C, Corman VM, Giesecke-Thiel C, Sander LE, Thiel A. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* 2020;587:270–4. doi:[10.1038/s41586-020-2598-9](https://doi.org/10.1038/s41586-020-2598-9).
- Bulfone TC, Malekinejad M, Rutherford GW, Razani N. Outdoor transmission of SARS-CoV-2 and other respiratory viruses: a systematic review. *J Infect Dis* 2021;223:550–61. doi:[10.1093/infdis/jiaa742](https://doi.org/10.1093/infdis/jiaa742).
- Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* 2020;20:269–70. doi:[10.1038/s41577-020-0308-3](https://doi.org/10.1038/s41577-020-0308-3).
- Chakrabarti S, Hamlet LC, Kaminsky J, Subramanian SV. Association of human mobility restrictions and race/ethnicity-based, sex-based, and income-based factors with inequities in well-being during the COVID-19 pandemic in the United States. *JAMA Netw. Open* 2021;4 –e217373. doi:[10.1001/jamanetworkopen.2021.7373](https://doi.org/10.1001/jamanetworkopen.2021.7373).
- Chou R, Dana T, Jungbauer R. Update alert 6: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. *Ann Intern Med* 2021. doi:[10.7326/L21-0393](https://doi.org/10.7326/L21-0393).
- Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, Cally R, Logre E, Fraissé M, Mentec H, Plantefève G. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive Care* 2020;10:119. doi:[10.1186/s13613-020-00736-x](https://doi.org/10.1186/s13613-020-00736-x).
- Cortés-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. *Pharmacol Rep PR* 2021;73:962–5. doi:[10.1007/s43440-021-00231-5](https://doi.org/10.1007/s43440-021-00231-5).
- de Sousa E, Ligeiro D, Lérias JR, Zungla C, Agrati C, Osman M, El-Kafrawy SA, Azhar El, Ippolito G, Wang F-S, Zhang A, Mauerer M. Mortality in COVID-19 disease patients: correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. *Int J Infect Dis* 2020;98:454–9. doi:[10.1016/j.ijid.2020.07.016](https://doi.org/10.1016/j.ijid.2020.07.016).
- Estola T. Coronaviruses, a new group of animal RNA viruses. *Avian Dis* 1970;14:330–6.
- Flandre D, Rentier B, Zizi MTeam Covidrationnel. Pour une stratégie de dépistage efficace et objective des personnes susceptibles de transmettre le SARS-CoV-2. *Blog Covidrationnel* 2021.
- Forcades i Vila T. Flu vaccination: the gap between evidence and public policy. *Int J Health Serv Plan Adm Eval* 2015;45:453–70. doi:[10.1177/0020731415585976](https://doi.org/10.1177/0020731415585976).
- Garvin MR, Alvarez C, Miller JJ, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *eLife* 2020;9:e59177. doi:[10.7554/eLife.59177](https://doi.org/10.7554/eLife.59177).
- Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *The Lancet* 2021;397:1603–5. doi:[10.1016/S0140-6736\(21\)00869-2](https://doi.org/10.1016/S0140-6736(21)00869-2).
- Hall VJ, Foulkes Sarah, Charlett Andre, Atti Ana, Monk EJM, Simmons Ruth, Wellington Edgar, Cole MJ, Saei Ayoub, Oguti Blanche, Munro Katie, Wallace Sarah, Kirwan PD, Shrotri Madhumita, Vusirikala Amoolya, Rokadiya Sakib, Kall Meaghan, Zambon Maria, Ramsay Mary, Brooks Tim, Brown CS, Chand MA, Hopkins Susan, Andrews N, Atti A, Aziz H, Brooks T, Brown C, Camero D, Carr C, Chand M, Charlett A, Crawford H, Cole M, Conneely J, D'Arcangelo S, Ellis J, Evans S, Foulkes S, Gillson N, Gopal R, Hall L, Hall V, Harrington P, Hopkins S, Hewson J, Hoshler K, Ironmonger D, Islam J, Kall M, Karagiannis I, Kay O, Khawam J, King E, Kirwan P, Kyffin R, Lackenby A, Lattimore M, Linley E, Lopez-Bernal J, Mabey L, McGregor R, Miah S, Monk E, Munro K, Naheed Z, Nissr A, O'Connell A, Oguti B, Okafor H, Organ S, Osborne R, Otter A, Patel M, Platt S, Pople D, Potts K, Ramsay M, Robotham J, Rokadiya S, Rowe C, Saei A, Sebbage G, Semper A, Shrotri M, Simmons R, Soriano A, Staves P, Taylor S, Taylor A, Tengbe A, Tonge S, Vusirikala A, Wallace S, Wellington E, Zambon M, Corrigan D, Sar-taj M, Cromey L, Campbell S, Braithwaite K, Price L, Haahr L, Stewart S, Lacey E, Partridge L, Stevens G, Ellis Y, Hodgson H, Norman C, Larru B, Mcwilliam S, Winchester S, Cieciva P, Pai A, Loughrey C, Watt A, Adair F, Hawkins A, Grant A, Temple-Purcell R, Howard J, Slawson N, Subudhi C, Davies S, Bexley A, Penn R, Wong N, Boyd G, Rajgopal A, Arenas-Pinto A, Matthews R, Whileman A, Laugharne R, Ledger J, Barnes T, Jones C, Botes D, Chitalia N, Akhtar S, Harrison G, Horne S, Walker N, Agwuh K, Maxwell V, Graves J, Williams S, O'Kelly A, Ridley P, Cowley A, Johnstone H, Swift P, Democratis J, Meda M, Calens C, Beazer S, Hams S, Irvine V, Chandrasekaran B, Forsyth C, Radmore J, Thomas C, Brown K, Roberts S, Burns P, Gajee K, Byrne T, Sanderson F, Knight S, Macnaughton E, Burton B, Smith H, Chaudhuri R, Hollinshead K, Shorten R, Swan A, Shorten R, Favager C, Murira J, Baillon S, Hamer S, Gantert K, Russell J, Brennan D, Dave A, Chawla A, Westell F, Adeboyeku D, Papieni P, Pegg C, Williams M, Ahmad S, Ingram S, Gabriel C, Pagget K, Cieciva P, Maloney G, Ashcroft J, Del Rosario I, Crosby-Nwaobi R, Reeks C, Fowler S, Prentice L, Spears M, McKerron G, McLelland-Brooks K, Anderson J, Donaldson S, Templeton K, Coke L, Elumogo N, Elliott J, Padgett D, Mirfenderesky M, Cross A, Price J, Joyce S, Sinanovic I, Howard M, Lewis T, Cowling P, Potoczna D, Brand S, Sheridan L, Wadams B, Lloyd A, Moulard J, Giles J, Pottinger G, Coles H, Joseph M, Lee M, Orr S, Chenoweth H, Auckland C, Lear R, Mahungu T, Rodger A, Penny-Thomas K, Pai S, Zamikula J, Smith E, Stone S, Boldock E, Howcroft D, Thompson C, Aga M, Domingos P, Gormley S, Kerrison C, Marsh L, Tazzyman S, All-sop L, Ambalkar S, Beekes M, Jose S, Tomlinson J, Jones A, Price C, Pepperell J, Schultz M, Day J, Boulos A, Defever E, McCracken D, Brown K, Gray K, Houston A, Planchet T, Pritchard Jones R, Wycherley D, Bennett S, Marrs J, Nimako K, Stewart B, Kalakonda N, Khanduri S, Ashby A, Holden M, Mahabir N, Harwood J, Payne B, Court K, Staines N, Longfellow R, Green M, Hughes L, Halles M, Mercer P, Roebuck A, Wilson-Davies E, Gallego L, Lazarus R, Aldridge N, Berry L, Game F, Reynolds T, Holmes C, Wiselka M, Higham A, Booth M, Duff C, Alderton J, Jory H, Virgilio E, Chin T, Qazafi M, Moody A, Tilley R, Donaghy T, Shipman K, Sierra R, Jones N, Mills G, Harvey D, Huang Y, Birch J, Robinson L, Board S, Broadley A, Laven C, Todd N, Eyre D, Jeffery K, Dunachie S, Duncan C, Klenerman P, Turtle L, De Silva T, Baxendale H, Heeney J. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *The Lancet* 2021;397:1459–69. doi:[10.1016/S0140-6736\(21\)00675-9](https://doi.org/10.1016/S0140-6736(21)00675-9).
- He S, Han J, Lichtfouse E. Backward transmission of COVID-19 from humans to animals may propagate reinfections and induce vaccine failure. *Environ Chem Lett* 2021;19:763–8. doi:[10.1007/s10311-020-01140-4](https://doi.org/10.1007/s10311-020-01140-4).
- Hill A, Garratt A, Levi J, Falconer J, Ellis L, McCann K, Pilkington V, Qavi A, Wang J, Wentzel H. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. *Open Forum Infect Dis* 2021. doi:[10.1093/ofid/ofab358](https://doi.org/10.1093/ofid/ofab358).
- Horton R. Offline: COVID-19 is not a pandemic. *The Lancet* 2020;396:874. doi:[10.1016/S0140-6736\(20\)32000-6](https://doi.org/10.1016/S0140-6736(20)32000-6).
- Hrynck TA, Ripoll Lorenzo S, Carter SE. COVID-19 response: mitigating negative impacts on other areas of health. *BMJ Glob Health* 2021;6. doi:[10.1136/bmjgh-2020-004110](https://doi.org/10.1136/bmjgh-2020-004110).
- Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, Wu Y, Sun L, Xu Y. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. *J Clin Virol* 2020;127. doi:[10.1016/j.jcv.2020.104371](https://doi.org/10.1016/j.jcv.2020.104371).
- Independent Panel for Pandemic Preparedness and Response, 2021. COVID-19: Make it the last pandemic.
- Intra J, Sarto C, Beck E, Tiberti N, Leoni V, Brambilla P. Bacterial and fungal colonization of the respiratory tract in COVID-19 patients should not be neglected. *Am J Infect Control* 2020;48:1130–1. doi:[10.1016/j.ajic.2020.06.185](https://doi.org/10.1016/j.ajic.2020.06.185).
- Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. *Bull World Health Organ*; 2020 <https://doi.org/BLT.20.265892>.
- Karmakar M, Lantz PM, Tipirneni R. Association of social and demographic factors with COVID-19 incidence and death rates in the US. *JAMA Netw. Open* 2021;4 –e2036462. doi:[10.1001/jamanetworkopen.2020.36462](https://doi.org/10.1001/jamanetworkopen.2020.36462).
- Langton, D.J., Bourke, S.C., Lie, B.A., Reiff, G., Natu, S., Darlay, R., Burn, J., Echevarria, C., 2021. The influence of HLA genotype on susceptibility to, and severity of, COVID-19 infection. *medRxiv* 2020.12.31.20249081. <https://doi.org/10.1101/2020.12.31.20249081>
- Loewenson R, Accoe K, Bajpai N, Buse K, Deivanayagam TA, London L, Méndez CA, Mirzoev T, Nelson E, Parry AA, Probandari A, Sarriot E, Tetui M, van Rensburg AJ. Reclaiming comprehensive public health. *BMJ Glob Health* 2020;5. doi:[10.1136/bmjgh-2020-003886](https://doi.org/10.1136/bmjgh-2020-003886).
- Loewenson R, Colvin CJ, Szabzon F, Das S, Khanna R, Coelho VSP, Gansane Z, Yao S, Asibu WD, Rome N, Nolan E. Beyond command and control: a rapid review of meaningful community-engaged responses to COVID-19. *Glob Public Health* 2021;1–15. doi:[10.1080/17441692.2021.1900316](https://doi.org/10.1080/17441692.2021.1900316).
- Margolin L, Luchins J, Margolin D, Margolin M, Lefkowitz S. 20-week study of clinical outcomes of over-the-counter COVID-19 prophylaxis and treatment. *J Evid-Based Integr Med* 2021;26 2515690X211026193. doi:[10.1177/2515690X211026193](https://doi.org/10.1177/2515690X211026193).
- McCartney M. We need better evidence on non-drug interventions for COVID-19. *BMJ* 2020;370:m3473. doi:[10.1136/bmj.m3473](https://doi.org/10.1136/bmj.m3473).
- Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* 2008;198:962–70. doi:[10.1086/591708](https://doi.org/10.1086/591708).
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections. *Annu Rev Virol* 2020;7:83–101. doi:[10.1146/annurev-virology-012420-022445](https://doi.org/10.1146/annurev-virology-012420-022445).
- Nielsen SS, Vibholm IK, Monrad I, Olesen R, Frattari GS, Pahuus MH, Hojen JF, Gunst JD, Erikstrup C, Holleufer A, Hartmann R, Østergaard L, Søgaard OS, Schleimann MH, Tolstrup M. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. *EBioMedicine* 2021;68. doi:[10.1016/j.ebiom.2021.103410](https://doi.org/10.1016/j.ebiom.2021.103410).
- O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, Cauchemez S, Salje H. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 2020. doi:[10.1038/s41586-020-2918-0](https://doi.org/10.1038/s41586-020-2918-0).
- OECD/European Union. Health at a glance: Europe 2020. Paris: State of health in the UE cycle; 2020.
- O'Hearn Meghan, Junxiu Liu, Frederick Cudhea, Renata Micha, Dariush Mozaffarian. Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis. *J Am Heart Assoc* 2021;10. doi:[10.1161/JAHA.120.019259](https://doi.org/10.1161/JAHA.120.019259).
- Paul E, Brown GW, Kalk A, Ridde V. Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager. *Vaccine* 2021. doi:[10.1016/j.vaccine.2021.07.045](https://doi.org/10.1016/j.vaccine.2021.07.045).
- Paul E, Brown GW, Kalk A, Van Damme W, Ridde V, Sturmberg JP. When my information changes, I alter my conclusions." What can we learn from the failures to adaptively respond to the SARS-Cov-2 pandemic and the under preparedness of health systems to manage COVID-19? *Int J Health Policy Manag* 2020a. doi:[10.34172/ijhpm.2020.240](https://doi.org/10.34172/ijhpm.2020.240).
- Paul E, Brown GW, Ridde V. COVID-19: time for paradigm shift in the nexus between local, national and global health. *BMJ Glob Health* 2020b;5. doi:[10.1136/bmjgh-2020-002622](https://doi.org/10.1136/bmjgh-2020-002622).

- Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis* 2020;71:2459–68. doi:[10.1093/cid/ciaa530](https://doi.org/10.1093/cid/ciaa530).
- Rocha R, Atun R, Massuda A, Rache B, Spinola P, Nunes L, Lago M, Castro MC. Effect of socioeconomic inequalities and vulnerabilities on health-system preparedness and response to COVID-19 in Brazil: a comprehensive analysis. *Lancet Glob Health* 2021;9:E782–92. doi:[10.1016/S2214-109X\(21\)00081-4](https://doi.org/10.1016/S2214-109X(21)00081-4).
- Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, So JBY, Goh BC, Loh KS, Fisher D, Teoh HL, Sun J, Cook AR, Tambyah PA, Hartman M. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. *Int J Infect Dis* 2021;106:314–22. doi:[10.1016/j.ijid.2021.04.035](https://doi.org/10.1016/j.ijid.2021.04.035).
- Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G, Chen H, Bu Z. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science* 2020;368:1016. doi:[10.1126/science.abb7015](https://doi.org/10.1126/science.abb7015).
- Shrestha, N.K., Burke, P.C., Nowacki, A.S., Terpeluk, P., Gordon, S.M., 2021. Necessity of COVID-19 vaccination in previously infected individuals. medRxiv 2021.06.01.21258176. <https://doi.org/10.1101/2021.06.01.21258176>
- Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, Brinsden H, Calvillo A, De Schutter O, Devarajan R, Ezzati M, Friel S, Goenka S, Hammond RA, Hastings G, Hawkes C, Herrero M, Hovmand PS, Howden M, Jaacks LM, Kapetanaki AB, Kasman M, Kuhnlein HV, Kumanyika SK, Larjani B, Lobstein T, Long MW, Matsudo VKR, Mills SDH, Morgan G, Morshed A, Nece PM, Pan A, Patterson DW, Sacks G, Shekar M, Simmons GL, Smit W, Tootee A, Vandevijvere S, Waterlander WE, Wolfenden L, Dietz WH. The global syndemic of obesity, undernutrition, and climate change: The Lancet Commission report. *Lancet Lond Engl* 2019;393:791–846. doi:[10.1016/S0140-6736\(18\)32822-8](https://doi.org/10.1016/S0140-6736(18)32822-8).
- The Lancet COVID-19 Commission, Task Force on Public Health Measures to Suppress the Pandemic. SARS-CoV-2 variants: the need for urgent public health action beyond vaccines. *The Lancet* 2021.
- The Lancet Infectious Diseases. The dengue vaccine dilemma. *Lancet Infect Dis* 2018;18:123. doi:[10.1016/S1473-3099\(18\)30023-9](https://doi.org/10.1016/S1473-3099(18)30023-9).
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. *N Engl J Med* 2020. doi:[10.1056/NEJMoa2021436](https://doi.org/10.1056/NEJMoa2021436).
- Tremblay M-C, Richard L, Brousselle A, Beaudet N. Learning reflexively from a health promotion professional development program in Canada. *Health Promot Int* 2014;29:538–48. doi:[10.1093/heapro/dat062](https://doi.org/10.1093/heapro/dat062).
- Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O'Halloran JA, Presti RM, Ellebedy AH. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature* 2021. doi:[10.1038/s41586-021-03647-4](https://doi.org/10.1038/s41586-021-03647-4).
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* 2020;395:1417–18. doi:[10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5).
- Varona JF, Landete P, Lopez-Martín JA, Estrada V, Paredes R, Guisado-Vasco P, de Orueta LF, Torralba M, Fortún J, Vates R, Barberán J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijón P, Monereo A, Abad D, Zúñiga S, Sola I, Rodon J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Girón de Velasco P, Sopesén B, Nieto A, Gómez J, Avilés P, Lubomirov R, White KM, Rosales R, Yildiz S, Reuschl A-K, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhadou M, Obernier K, Enjuanes L, Fernández-Sousa JM, Krogan NJ, Jimeno JM, García-Sastre A. Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. *MedRxiv Prepr Serv Health Sci* 2021. doi:[10.1101/2021.05.25.21257505](https://doi.org/10.1101/2021.05.25.21257505).
- Vaughn VM, Yost M, Abshire C, Flanders SA, Paje D, Grant P, Kaatz S, Kim T, Barnes GD. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. *JAMA Netw Open* 2021;4 –e2111788. doi:[10.1001/jamanetworkopen.2021.11788](https://doi.org/10.1001/jamanetworkopen.2021.11788).
- Verroken A, Scohy A, Gérard L, Wittebole X, Collienne C, Laterre P-F. Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis. *Crit Care* 2020;24:410. doi:[10.1186/s13054-020-03135-7](https://doi.org/10.1186/s13054-020-03135-7).
- Wardeh M, Baylis M, Blagrove MSC. Predicting mammalian hosts in which novel coronaviruses can be generated. *Nat Commun* 2021;12:780. doi:[10.1038/s41467-021-21034-5](https://doi.org/10.1038/s41467-021-21034-5).
- Wernli D, Tediosi F, Blanchet K, Lee K, Morel C, Pittet D, Levrat N, Young O. A complexity lens on the COVID-19 pandemic. *Int J Health Policy Manag* 2021. doi:[10.34172/ijhpm.2021.55](https://doi.org/10.34172/ijhpm.2021.55).
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020. doi:[10.1001/jama.2020.12839](https://doi.org/10.1001/jama.2020.12839).
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas JJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020. doi:[10.1038/s41586-020-2521-4](https://doi.org/10.1038/s41586-020-2521-4).
- World Health Organization. Health systems for health security: a framework for developing capacities for international health regulations, and components in health systems and other sectors that work in synergy to meet the demands imposed by health emergencies. Geneva, Switzerland: World Health Organization; 2021.
- World Health Organization, 2020. WHO Director-General's opening remarks at the media briefing on COVID-19 – 12 October 2020. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-12-october-2020>.
- Ye Z-W, Yuan S, Yuen K-S, Fung S-Y, Chan C-P, Jin D-Y. Zoonotic origins of human coronaviruses. *Int J Biol Sci* 2020;16:1686–97. doi:[10.7150/ijbs.45472](https://doi.org/10.7150/ijbs.45472).